High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis
A high primary tumor expression of CTLA4 identifies patients with an excellent prognosis, for whom standard chemotherapy may be de-escalated or omitted.
Authors
- Esmaeil Dorraji (ORCID: https://orcid.org/0000-0003-1619-6610)
- Bjørn Naume (ORCID: https://orcid.org/0000-0002-6811-9476)
- Ole Christian Lingjærde (ORCID: https://orcid.org/0000-0003-3565-4912)
- Johan Vallon‐Christersson (ORCID: https://orcid.org/0000-0002-2195-0385)
- Hege Giercksky Russnes (ORCID: https://orcid.org/0000-0001-8724-1891)
- Andreas Hagen Røssevold (ORCID: https://orcid.org/0000-0002-7212-0111)
- Elin Borgen (ORCID: https://orcid.org/0000-0002-6633-3073)
- Jon Amund Kyte (ORCID: https://orcid.org/0000-0002-2854-3694)
- Jon Lømo
- Vessela Nedelcheva Kristensen (ORCID: https://orcid.org/0000-0001-5012-7438)
- Xavier Tekpli (ORCID: https://orcid.org/0000-0003-4042-8290)
- Øystein Garred
Institutions
- Oslo University Hospital (NO)
- OsloMet – Oslo Metropolitan University (NO)
- University of Oslo (NO)
- Lund University (SE)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1038/s43856-025-00865-z
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09